The Technical Analyst
Quanta, Inc. [QNTA]
Exchange: PNK Industry: Household & Personal Products
Quanta, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0001
America/New_York / 15 mai 2023 @ 15:41
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0407 mill |
| EPS: | 0.0100 |
| P/E: | 0.0100 |
| Earnings Date: | May 23, 2022 |
| SharesOutstanding: | 406.59 mill |
| Avg Daily Volume: | 0.0612 mill |
| RATING 2023-05-15 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0.0100 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE 0.0100 | industry: PE 4.94 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0001 - 0.0001 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2020-07-02 | Rice Eric | Buy | 1 500 | Common Stock |
| 2020-06-26 | Rice Eric | Buy | 1 500 | Common Stock |
| 2020-06-24 | Rice Eric | Buy | 1 500 | Common Stock |
| 2020-06-22 | Rice Eric | Buy | 1 000 | Common Stock |
| 2020-06-19 | Rice Eric | Buy | 2 000 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 98 transactions |
| Buy: 5 562 440 | Sell: 2 784 614 |
Forecast:
01:40 - $0
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0001 (0.00% ) |
| Volume | 0.0310 mill |
| Avg. Vol. | 0.0612 mill |
| % of Avg. Vol | 50.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For QNTA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
QNTA
Quanta, Inc., an applied science company, provides pharmaceutical, nutraceutical, topical relief, and cosmetic products in the United States. The company offers contract research services, including research, development, and production of pharmaceutical-grade products, as well as clinical evidence-based nutraceuticals utilizing patented polarization technology. It also manufactures and distributes consumer wellness products in areas of pain relief, beauty, and general wellness. The company was founded in 2016 and is headquartered in Burbank, California.
Latest Press Releases
2021-11-19 08:00:00 - Press Release
Medolife Rx Schedules Conference Call With Investment Community To Discuss Third Quarter 2021 Financial And Operational Results And New Updates
Burbank, calif., nov. 19, 2021 (globe newswire) -- via newmediawire – medolife rx, inc. ("medolife"), a global integrated bioceutical company with r&d, manufacturing, and consumer product distribution, which is a majority owned subsidiary of quanta, inc. (otcqb: qnta), announced today that it has scheduled a conference call with investors for tuesday, november 23rd.
2021-10-14 08:30:00 - Press Release
Medolife Rx Announces That The Government Of The Dominican Republic Is Willing To Include Escozine Into Its Covid-19 Treatment Regimen
Burbank, calif., oct. 14, 2021 (globe newswire) -- via newmediawire -- medolife rx, inc. ("medolife"), a global integrated biopharmaceutical company with r&d, manufacturing, and consumer product distribution, which is a majority owned subsidiary of quanta, inc. (otcqb: qnta), announced today that its ceo, dr arthur mikaelian, had a successful meeting with the vice president of the dominican republic (dr), raquel peÑa de antuÑa, where the official expressed interest in introducing escozine® into the government's covid-19 program after reviewing results from the company's study.
2021-10-12 08:30:00 - Press Release
Medolife Rx Reports 257% Increase In Efficacy Of Ibuprofen Through Proprietary Polarization Method, Looks To Expand Into Other Apis
Burbank, calif., oct. 12, 2021 (globe newswire) -- via newmediawire – medolife rx, inc. ("medolife"), a global integrated biopharmaceutical company with r&d, manufacturing, and consumer product distribution, which is a majority owned subsidiary of quanta, inc. (otcqb: qnta), announced today results from a study on its patented polarization methodology that compared the effectiveness of generic ibuprofen, a well-known pain relief drug that works by lowering inflammation by inhibiting the cyclooxygenase-2 (cox-2) enzyme's activity in the body, versus polarized ibuprofen in inhibition of cox-2 activity in humans. the results showed that polarized ibuprofen was 257% more effective in inhibiting cox-2, which is expressed in inflammation and pain in humans...
2021-10-06 08:30:00 - Press Release
Medolife Rx Initiates Comparative Study Of Its Flagship Cbd-based Muscle Rub And Competitor
Burbank, calif., oct. 06, 2021 (globe newswire) -- via newmediawire – medolife rx, inc. ("medolife"), a global integrated biopharmaceutical company with r&d, manufacturing, and consumer product distribution, which is a majority owned subsidiary of quanta, inc. (otcqb: qnta), announced today that it has initiated a study on its polarized cannabidiol (cbd) muscle rub product, sold under the brand aelia. the study will analyze the effectiveness of the product in reducing inflammation through the inhibition of cyclooxygenase-2 (cox-2) enzyme activity in the human body and compare the findings with other non-polarized cbd products currently available on the market.
2021-09-29 08:30:00 - Press Release
Medolife Rx Files Bi-annual Report With Ministry Of Environment In The Dominican Republic, Details Reservation Expansion And Exceeds Regulatory Expectations
Burbank, calif., sept. 29, 2021 (globe newswire) -- via newmediawire – medolife rx, inc. ("medolife"), a global integrated bioceutical company with r&d, manufacturing, and consumer product distribution, which is a majority owned subsidiary of quanta, inc. (otcqb: qnta), announced today that it has completed a bi-annual filing with the ministry of environment (moe) of the dominican republic (dr), which detailed the expansion of its scorpion reservation and exceeded the expectations of the regulatory body. the moe expressed further interest in the company's flagship product, escozine®, which has recently renewed its registration in the dr as a natural alternative medicine for oncological treatments.
Latest News
2021-11-19 08:00:00 - GlobeNewsWire
Medolife Rx Schedules Conference Call with Investment Community To Discuss Third Quarter 2021 Financial and Operational Results and New Updates
BURBANK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that it has scheduled a conference call with investors for Tuesday, November 23rd.
2021-10-14 08:30:00 - GlobeNewsWire
Medolife Rx Announces that the Government of the Dominican Republic is Willing to Include Escozine into its COVID-19 Treatment Regimen
BURBANK, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that its CEO, Dr Arthur Mikaelian, had a successful meeting with the Vice President of the Dominican Republic (DR), Raquel Peña de Antuña, where the official expressed interest in introducing Escozine® into the government's COVID-19 program after reviewing results from the Company's study.
2021-10-12 08:30:00 - GlobeNewsWire
Medolife Rx Reports 257% Increase in Efficacy of Ibuprofen Through Proprietary Polarization Method, Looks to Expand Into Other APIs
BURBANK, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today results from a study on its patented polarization methodology that compared the effectiveness of generic ibuprofen, a well-known pain relief drug that works by lowering inflammation by inhibiting the cyclooxygenase-2 (COX-2) enzyme's activity in the body, versus polarized ibuprofen in inhibition of COX-2 activity in humans. The results showed that polarized ibuprofen was 257% more effective in inhibiting COX-2, which is expressed in inflammation and pain in humans...
2021-10-06 08:30:00 - GlobeNewsWire
Medolife Rx Initiates Comparative Study of Its Flagship CBD-based Muscle Rub and Competitor
BURBANK, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that it has initiated a study on its polarized cannabidiol (CBD) muscle rub product, sold under the brand Aelia. The study will analyze the effectiveness of the product in reducing inflammation through the inhibition of cyclooxygenase-2 (COX-2) enzyme activity in the human body and compare the findings with other non-polarized CBD products currently available on the market.
2021-09-29 08:30:00 - GlobeNewsWire
Medolife Rx Files Bi-Annual Report With Ministry of Environment in the Dominican Republic, Details Reservation Expansion and Exceeds Regulatory Expectations
BURBANK, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that it has completed a bi-annual filing with the Ministry of Environment (MOE) of the Dominican Republic (DR), which detailed the expansion of its scorpion reservation and exceeded the expectations of the regulatory body. The MOE expressed further interest in the Company's flagship product, Escozine®, which has recently renewed its registration in the DR as a natural alternative medicine for oncological treatments.
2021-09-23 10:47:00 - GlobeNewsWire
Medolife Rx Launches Ad Campaign With Tony Hawk, Sees Immediate Positive Results
BURBANK, CA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today the successful launch of a digital advertising campaign for its Aelia line of products featuring product spokesperson Tony Hawk. The campaign launched nationwide on September 16, 2021, and has already garnered hundreds of thousands of impressions and resulted in a traffic spike to the Company's website when compared to the previous 20 days.
2021-09-21 18:09:00 - GlobeNewsWire
Medolife Rx Clarifies April 13, 2021 Press Release
BURBANK, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife" or the “Company”), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today two clarifications to its press release, dated April 13, 2021:
2021-09-01 10:40:00 - GlobeNewsWire
Medolife Rx Recaps Successful Attendance at Tony Hawk Event; Saw Significant Product Exposure
BURBANK, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), today recapped their attendance at the Inaugural Tony Hawk's Vert Alert event in Salt Lake City the weekend of August 27 and 28. The Company showcased its rebranded line of consumer wellness products, participated in skateboarding community discussions and events, and met with Hawk himself as well as his management team, where the parties discussed meeting soon to increase their joint initiatives aimed at further reaching the skateboarding community worldwide with Aelia products.
2021-08-23 17:15:00 - GlobeNewsWire
Medolife Rx Reports Second Quarter 2021 Financial and Operational Results, Schedules Conference Call With Investment Community
BURBANK, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today financial results for the second quarter of 2021, and provided an operational update.
2021-07-21 11:04:00 - GlobeNewsWire
Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021
BURBANK, CA, July 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it will hold a webcast and Q&A with the investment community on Tuesday, July 27, at 5 p.m. Eastern Daylight Time. The purpose of this is to answer questions received from the investment community all at one time in an open forum.